Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- PMID: 35613033
- DOI: 10.1056/NEJMc2118470
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Comment in
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply.N Engl J Med. 2022 May 26;386(21):e57. doi: 10.1056/NEJMc2118470. N Engl J Med. 2022. PMID: 35613034 No abstract available.
Comment on
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. N Engl J Med. 2021. PMID: 34449189 Clinical Trial.
Similar articles
-
Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction.Clin Med (Lond). 2022 Jan;22(1):75-76. doi: 10.7861/clinmed.rib.22.1.1. Clin Med (Lond). 2022. PMID: 35078797 Free PMC article. No abstract available.
-
Evidence for empagliflozin in heart failure with preserved ejection fraction (HFpEF).Drug Ther Bull. 2023 Feb;61(2):22-23. doi: 10.1136/dtb.2022.000060. Epub 2022 Dec 12. Drug Ther Bull. 2023. PMID: 36600444
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.N Engl J Med. 2022 May 26;386(21):e57. doi: 10.1056/NEJMc2118470. N Engl J Med. 2022. PMID: 35613032 No abstract available.
-
Pharmacologic Management for Heart Failure and Emerging Therapies.Curr Cardiol Rep. 2017 Aug 24;19(10):94. doi: 10.1007/s11886-017-0899-x. Curr Cardiol Rep. 2017. PMID: 28840572 Review.
-
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.JACC Heart Fail. 2018 Aug;6(8):633-639. doi: 10.1016/j.jchf.2018.01.009. Epub 2018 Mar 7. JACC Heart Fail. 2018. PMID: 29525327 Review.
Cited by
-
Global historical retrospect and future prospects on biomarkers of heart failure: A bibliometric analysis and science mapping.Heliyon. 2023 Feb 7;9(2):e13509. doi: 10.1016/j.heliyon.2023.e13509. eCollection 2023 Feb. Heliyon. 2023. PMID: 36825183 Free PMC article.
-
Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence.J Cardiovasc Dev Dis. 2025 Jan 7;12(1):19. doi: 10.3390/jcdd12010019. J Cardiovasc Dev Dis. 2025. PMID: 39852297 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical